[HTML][HTML] Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy
During the last decades, the pleiotropic antitumor functions exerted by type I interferons
(IFNs) have become universally acknowledged, especially their role in mediating …
(IFNs) have become universally acknowledged, especially their role in mediating …
Perspectives for combining viral oncolysis with additional immunotherapies for the treatment of melanoma
OLD Cerqueira, F Antunes, NG Assis… - Frontiers in Molecular …, 2022 - frontiersin.org
Melanoma is the deadliest type of skin cancer with steadily increasing incidence worldwide
during the last few decades. In addition to its tumor associated antigens (TAAs), melanoma …
during the last few decades. In addition to its tumor associated antigens (TAAs), melanoma …
A therapeutic vaccine in combination with cyclic GMP–AMP cures more differentiated melanomas in mice
We have identified a combinational immunotherapy termed TheraVac vaccine (TheraVac)
that can cure multiple large established mouse tumors, but it failed to cure melanoma in …
that can cure multiple large established mouse tumors, but it failed to cure melanoma in …
Combination of cabazitaxel and p53 gene therapy abolishes prostate carcinoma tumor growth
RE Tamura, MG Lana, E Costanzi-Strauss, BE Strauss - Gene therapy, 2020 - nature.com
For patients with metastatic prostate cancer, the 5-year survival rate of 31% points to a need
for novel therapies and improvement of existing modalities. We propose that p53 gene …
for novel therapies and improvement of existing modalities. We propose that p53 gene …
Reestablishment of p53/Arf and interferon-β pathways mediated by a novel adenoviral vector potentiates antiviral response and immunogenic cell death
Malignant melanoma is a type of cancer with high death rates due, in part, to the lack of
efficient treatments once metastases have formed. 1 The tumor suppressor protein p53 is …
efficient treatments once metastases have formed. 1 The tumor suppressor protein p53 is …
[HTML][HTML] Intratumoral immunization by p19Arf and interferon-β gene transfer in a heterotopic mouse model of lung carcinoma
JPP Catani, RFV Medrano, A Hunger, P Del Valle… - Translational …, 2016 - Elsevier
Therapeutic strategies that act by eliciting and enhancing antitumor immunity have been
clinically validated as an effective treatment modality but may benefit from the induction of …
clinically validated as an effective treatment modality but may benefit from the induction of …
[HTML][HTML] TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells
High basal or induced expression of the tripartite motif protein, TRIM16, leads to reduce cell
growth and migration of neuroblastoma and skin squamous cell carcinoma cells. However …
growth and migration of neuroblastoma and skin squamous cell carcinoma cells. However …
Induction of oxidants distinguishes susceptibility of prostate carcinoma cell lines to p53 gene transfer mediated by an improved adenoviral vector
Previously, the authors developed an adenoviral vector, Ad-PG, where transgene
expression is regulated by a p53-responsive promoter. When used to transfer the p53 cDNA …
expression is regulated by a p53-responsive promoter. When used to transfer the p53 cDNA …
Vaccination using melanoma cells treated with p19arf and interferon beta gene transfer in a mouse model: a novel combination for cancer immunotherapy
RFV Medrano, JPP Catani, AH Ribeiro… - Cancer Immunology …, 2016 - Springer
Previously, we combined p19 Arf (Cdkn2a, tumor suppressor protein) and interferon beta
(IFN-β, immunomodulatory cytokine) gene transfer in order to enhance cell death in a …
(IFN-β, immunomodulatory cytokine) gene transfer in order to enhance cell death in a …
Potentiation of combined p19Arf and interferon-beta cancer gene therapy through its association with doxorubicin chemotherapy
Balancing safety and efficacy is a major consideration for cancer treatments, especially
when combining cancer immunotherapy with other treatment modalities such as …
when combining cancer immunotherapy with other treatment modalities such as …